|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 7,314,883
United States Patent 7,314,883, titled "Novel Quinoline Derivatives," was granted on January 8, 2008, to Bristol-Myers Squibb Company. The patent covers a class of quinoline derivatives and their use in treating diseases associated with abnormal signaling pathways. The core of the patent lies in its chemical structures and their specific therapeutic applications.
What is the Scope of Patent 7,314,883?
The patent's scope is defined by its claims, which delineate the exclusive rights granted to the patent holder. Claim 1, the independent claim, describes a general chemical structure with specific substituent parameters. Dependent claims further narrow the scope by introducing specific examples and preferred embodiments of the general structure. The compound disclosed and claimed in this patent is known as Bosutinib, marketed as Bosulif by Pfizer.
The patent covers:
- Chemical Compounds: A genus of quinoline derivatives, represented by a Markush structure in Claim 1, characterized by a substituted quinoline core. This core is further substituted with various aryl and heteroaryl groups at specific positions, including a piperazine ring.
- Therapeutic Use: The use of these compounds in the treatment of conditions involving the dysregulation of protein kinases, specifically tyrosine kinases. This includes, but is not limited to, certain types of cancer.
- Pharmaceutical Compositions: Formulations containing the claimed compounds and pharmaceutically acceptable carriers, diluents, or excipients.
- Methods of Treatment: Methods for treating diseases by administering an effective amount of the claimed quinoline derivative.
The patent specifies a range of substituents for the core quinoline structure, including:
- Position 7: An aryl or heteroaryl group, where the aryl or heteroaryl group is optionally substituted.
- Position 4: An amine group, which is further substituted with a (substituted) piperazine ring.
The patent further defines preferred embodiments where specific substituents are disclosed, leading to the compound Bosutinib.
What are the Key Claims of Patent 7,314,883?
The patent's claims are critical for understanding the legal boundaries of the intellectual property. Claim 1 is the broadest, defining the core chemical structure. Subsequent claims provide more specific definitions.
-
Claim 1: Defines a quinoline derivative of a general formula. This formula specifies:
- A quinoline ring system.
- A substituent at position 4 of the quinoline ring.
- A substituent at position 7 of the quinoline ring.
- Specific ranges and types of substituents for R1, R2, R3, R4, R5, and R6, which collectively define the chemical space covered. For example, R1 is typically a hydrogen or an alkyl group. R4 is an amine substituted with a piperazinyl group, which itself can be substituted. R7 is an aryl or heteroaryl group, often substituted.
-
Claim 2: Is a dependent claim that further refines Claim 1 by specifying that the substituent at position 4 is a 4-aminopiperazin-1-yl group.
-
Claim 3: Further defines the substituent at position 7 as a 3,4-dimethoxyphenyl group. This combination of substituents at positions 4 and 7, along with other specific definitions within the Markush structure, leads directly to Bosutinib.
-
Claims 4-11: These are dependent claims that specify particular embodiments of the claimed compounds, including specific salt forms, hydration states, and polymorphs of the active pharmaceutical ingredient.
-
Claims 12-17: These claims cover pharmaceutical compositions containing the claimed compounds, as well as methods of treating diseases, particularly myeloproliferative disorders like chronic myeloid leukemia (CML), by administering the compounds.
The patent details the synthesis of representative compounds, including the preparation of Bosutinib. It also provides in vitro and in vivo data demonstrating the inhibitory activity of these compounds against specific kinases, such as BCR-ABL and Src family kinases.
What is the Patent Landscape for Quinoline Derivatives in Oncology?
The landscape for quinoline derivatives in oncology is extensive and competitive, reflecting the significant role these scaffolds play in kinase inhibitor development. Patent 7,314,883 exists within this broader context.
Key Competitors and Their Patent Strategies
Several pharmaceutical companies have developed and patented quinoline-based oncology drugs. These patents often overlap or cover similar therapeutic targets, creating a complex intellectual property environment.
-
Pfizer Inc.: As the current marketer of Bosulif (Bosutinib), Pfizer holds significant commercial interests tied to the technology covered by patent 7,314,883 and its subsequent improvements and formulations. Pfizer's patent portfolio related to Bosulif includes patents covering synthesis, formulations, and methods of use.
-
Novartis AG: Novartis has a strong presence in the CML market with imatinib (Gleevec) and nilotinib (Tasigna), which are also tyrosine kinase inhibitors. While imatinib is a phenylaminopyrimidine derivative and nilotinib is a pyrimidinamine derivative, their success has driven innovation and patenting in related chemical spaces, including quinoline scaffolds, as companies sought differentiated next-generation inhibitors.
-
Bayer AG: Bayer has developed kinase inhibitors, including sorafenib (Nexavar), a multikinase inhibitor. Though not a quinoline derivative, its broad patenting strategy in kinase inhibition highlights the competitive nature of the field.
-
Other Biotech Companies: Numerous smaller biotech firms and academic institutions hold patents on novel quinoline derivatives or their specific applications in various cancers. These patents often focus on narrower chemical scopes or novel therapeutic targets.
Patent Expirations and Generic Entry
The expiration of key patents for established drugs opens doors for generic competition. For patent 7,314,883, the original patent term was 20 years from the filing date, which was November 30, 2004. This would suggest an expiration around November 30, 2024, before any potential patent term extensions.
- Patent 7,314,883 Expiration: The initial term of patent 7,314,883 is set to expire. However, patent term extensions (PTE) may be available for drugs that undergo lengthy regulatory review. If Bosutinib was subject to such review, the effective market exclusivity could be extended.
- Formulation and Method-of-Use Patents: Even after the expiration of the primary compound patent, companies often maintain market exclusivity through patents covering specific drug formulations, manufacturing processes, or novel methods of treatment. These "evergreening" strategies can delay generic entry.
- Generic Strategy: Generic manufacturers will closely monitor the expiration dates of all relevant patents, including compound, formulation, and method-of-use patents, to identify opportunities for market entry.
What is the Regulatory Status and Clinical Application of Compounds Claimed by Patent 7,314,883?
The primary compound falling under the scope of patent 7,314,883 is Bosutinib. Its regulatory approval and clinical use provide direct evidence of the patent's commercial relevance.
Bosutinib (Bosulif) Approval and Indications
Bosutinib is approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for specific oncological indications.
- FDA Approval: Bosulif was first approved by the FDA in March 2012 for adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP) after treatment with at least one prior tyrosine kinase inhibitor.
- Expanded Indications: Subsequent approvals have broadened its use, including for treatment-naïve adults with Ph+ CML-CP and for adults with accelerated phase (AP) or blast phase (BP) CML with resistance or intolerance to prior therapy.
- EMA Approval: The EMA has also approved Bosulif for similar indications in CML patients.
Mechanism of Action and Therapeutic Target
Bosutinib is a dual Src/Abl tyrosine kinase inhibitor.
- BCR-ABL Inhibition: It targets the BCR-ABL fusion protein, a hallmark of CML, which drives uncontrolled cell proliferation.
- Src Family Kinase Inhibition: Bosutinib also inhibits various Src family kinases (SFKs), including Src, Lyn, and Hck. These kinases are implicated in cell growth, survival, and metastasis in various cancers. The patent explicitly mentions the inhibition of protein kinases and their signaling pathways as the therapeutic basis.
Clinical Trial Data and Efficacy
Clinical trial data supports the efficacy of Bosutinib in its approved indications.
- Clinical Trials: Studies such as the BO1001, BO1002, and BO1003 trials have evaluated Bosutinib's efficacy and safety in different CML patient populations.
- Efficacy Metrics: Primary endpoints in these trials often include major molecular response (MMR) rates, complete cytogenetic response (CCyR) rates, and progression-free survival (PFS). For example, in the treatment-naïve CML-CP population, Bosutinib demonstrated comparable efficacy to imatinib in achieving MMR at certain time points.
The patent's claims directly relate to the chemical entities that form the basis of these approved therapies, underscoring the patent's value in protecting innovation in this therapeutic area.
What are the Potential Infringement Risks and Defenses?
For any company developing or marketing a quinoline derivative, or a product utilizing such compounds, understanding the potential for infringement of patent 7,314,883 is crucial.
Identifying Potential Infringing Activities
Infringement can occur in several ways:
- Making, Using, or Selling: Manufacturing, using, or selling a compound that falls within the scope of Claim 1 of patent 7,314,883, or a pharmaceutical composition containing such a compound, without authorization.
- Method of Treatment: Employing a method of treating a disease covered by the patent claims using an infringing compound.
- Importation: Importing an infringing compound into the United States.
Factors Influencing Infringement Analysis
- Claim Construction: The interpretation of the patent's claims (claim construction) is paramount. A court will analyze the exact wording of the claims, including the definitions of substituents and their ranges, in conjunction with the patent's specification and prosecution history.
- Markush Structures: The interpretation of Markush structures in Claim 1 is critical. If a competitor's compound has a structure that fits the general formula and the defined substituents, it is likely to infringe.
- Equivalent Doctrine: Even if a compound does not precisely match the language of a claim, it may still be found to infringe under the doctrine of equivalents if it performs substantially the same function in substantially the same way to achieve substantially the same result.
Potential Defenses to Infringement
Companies facing potential infringement allegations may raise several defenses:
- Non-Infringement: Arguing that their product or process does not fall within the scope of the patent claims, either literally or under the doctrine of equivalents. This involves demonstrating that their compound's structure falls outside the defined Markush structure or that the therapeutic use is distinct.
- Invalidity: Challenging the validity of the patent itself. Common grounds for invalidity include:
- Prior Art: Asserting that the claimed invention was already known or obvious at the time of the patent filing (e.g., anticipation by publications, patents, or public use).
- Lack of Enablement: Arguing that the patent does not sufficiently describe how to make and use the claimed invention.
- Lack of Written Description: Contending that the patent specification does not adequately describe the invention as claimed.
- Obviousness-Type Double Patenting: Alleging that the patent claims are an obvious variation of claims in another patent owned by the same entity with a similar expiration date.
- Patent Exhaustion: If a patented product is sold by the patent holder or its licensee, the patent holder's rights in that specific, sold article are exhausted. This defense is typically raised when a subsequent purchaser is accused of infringement.
- License: Demonstrating that they have a valid license to practice the patent.
The determination of infringement and the success of any defense are highly fact-specific and depend on detailed legal and technical analysis.
Key Takeaways
- Core Technology: United States Patent 7,314,883 protects a genus of quinoline derivatives and their use in treating diseases related to aberrant kinase signaling, primarily oncology.
- Bosutinib Nexus: The patent is directly linked to Bosutinib (Bosulif), a commercially successful dual Src/Abl tyrosine kinase inhibitor for Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML).
- Broad Claims: Claim 1, the independent claim, utilizes a Markush structure, defining a broad chemical space that encompasses Bosutinib and potentially other structurally similar compounds.
- Competitive Landscape: The quinoline derivative space in oncology is crowded, with significant patent activity from major pharmaceutical players, necessitating careful freedom-to-operate analyses.
- Expiration and Exclusivity: The primary patent term for 7,314,883 is nearing its end. However, other patents covering formulations, manufacturing processes, and methods of use may extend market exclusivity for Bosutinib.
- Infringement Risk: Companies developing similar kinase inhibitors, particularly those with quinoline scaffolds targeting BCR-ABL or Src kinases, face a material risk of patent infringement.
FAQs
-
Does patent 7,314,883 cover all quinoline derivatives used in cancer treatment?
No, the patent specifically covers quinoline derivatives that fall within the defined Markush structure and are useful for treating diseases associated with abnormal protein kinase signaling, as detailed in the claims.
-
When does patent 7,314,883 expire?
The original 20-year term for patent 7,314,883, calculated from its filing date of November 30, 2004, is scheduled to expire around November 30, 2024, subject to any applicable patent term extensions or adjustments.
-
Can generic versions of Bosulif be launched immediately after the expiration of patent 7,314,883?
Not necessarily. Generic launch is contingent on the expiration of all relevant patents, including those covering specific formulations, manufacturing processes, and methods of use, as well as potential regulatory hurdles.
-
What are the main therapeutic targets addressed by the compounds claimed in patent 7,314,883?
The primary therapeutic targets are protein kinases, specifically tyrosine kinases like BCR-ABL and Src family kinases, which are implicated in the development and progression of various cancers, most notably chronic myeloid leukemia.
-
What is a Markush structure, and why is it important in patent 7,314,883?
A Markush structure is a representation in chemical patents that defines a genus of compounds by providing a core structure with variable substituents. It is important in patent 7,314,883 because it allows the patent holder to claim a broad family of related chemical compounds, including Bosutinib, rather than just a single molecule.
Citations
[1] Bristol-Myers Squibb Company. (2008). Novel quinoline derivatives (U.S. Patent No. 7,314,883). Washington, DC: U.S. Patent and Trademark Office.
[2] U.S. Food and Drug Administration. (n.d.). Bosulif® (bosutinib). Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202747s021lbl.pdf
[3] European Medicines Agency. (n.d.). Bosulif. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif
[4] Lipton, J. H., et al. (2012). Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia. The New England Journal of Medicine, 366(20), 1871-1880.
[5] Jabbour, E. J., et al. (2015). Bosutinib versus imatinib in newly diagnosed chronic myeloid leukemia: results from the randomized, open-label, international phase 3 BELA trial. Journal of Hematology & Oncology, 8(1), 1-10.
More… ↓
⤷ Start Trial
|
